# Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

> **NCT05270057** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 11 (actual)

## Conditions studied

- B-cell Lymphoma
- Burkitt Lymphoma

## Interventions

- **DRUG:** Etoposide
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Rituximab
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Loncastuximab Tesirine 0.075 mg/kg by IV
- **DRUG:** Loncastuximab tesirine 0.12 mg/kg by IV
- **DRUG:** Loncastuximab tesirine 0.15 mg/kg by IV

## Key facts

- **NCT ID:** NCT05270057
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-26
- **Primary completion:** 2025-05-28
- **Final completion:** 2027-10-11
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05270057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05270057, "Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05270057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*